Loading...
•
Sep 30, 2021
Rigel Q3 2021 Earnings Report
Reported a net loss due to increased research and development costs related to the ongoing Phase 3 clinical trial of fostamatinib for the treatment of hospitalized patients with COVID-19, as well as increased commercial activities, including the recent sales force expansion.
Key Takeaways
Rigel Pharmaceuticals reported a net loss of $21.0 million, or $0.12 per basic and diluted share, with total revenues of $21.5 million. TAVALISSE net product sales were $16.0 million, a decrease of 2% from the same period in 2020.
Net loss of $21.0 million, or $0.12 per basic and diluted share.
Total revenues were $21.5 million.
TAVALISSE net product sales were $16.0 million, a decrease of 2% from the same period in 2020.
Completed enrollment of pivotal FORWARD study in wAIHA, with anticipated data readout in mid-2022.
Revenue by Segment
Forward Guidance
Rigel anticipates a transformative year in 2022 with pipeline candidates advancing in the clinic and sales force expansion complete.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...